Fermenta Biotech (NSE:FERMENTA) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:FERMENTA Fermenta Biotech Ltd NSE:FERMENTA
54 GF Score
Price ₹456.10
GF Value ₹315.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Fermenta Biotech Cyclically Adjusted Revenue per Share?

Fermenta Biotech NSE:FERMENTA 54 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:FERMENTA with a GF Score™ of 54/100 and a GF Value™ of ₹315.37 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fermenta Biotech's adjusted revenue per share for the three months ended in Jun. 2026 was ₹41.783. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Fermenta Biotech's average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fermenta Biotech was 8.90% per year. The lowest was 8.50% per year. And the median was 8.60% per year.

As of today (2026-08-20), Fermenta Biotech's current stock price is ₹456.10. Fermenta Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Fermenta Biotech's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fermenta Biotech was 3.79. The lowest was 0.90. And the median was 2.12.


Fermenta Biotech  (NSE:FERMENTA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fermenta Biotech was 3.79. The lowest was 0.90. And the median was 2.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fermenta Biotech Cyclically Adjusted Revenue per Share Related Terms


Fermenta Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fermenta Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fermenta Biotech Cyclically Adjusted Revenue per Share Chart

Fermenta Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fermenta Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:FERMENTA vs : Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fermenta Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fermenta Biotech Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fermenta Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fermenta Biotech's Cyclically Adjusted PS Ratio falls into.


NSE:FERMENTA
54GF Score
Fermenta Biotech Ltd NSE:FERMENTA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fermenta Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fermenta Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=41.783/333.9520*333.9520
=41.783

Current CPI (Jun. 2026) = 333.9520.

Fermenta Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 14.571 241.428 20.155
201612 13.658 241.432 18.892
201703 16.021 243.801 21.945
201706 15.862 244.955 21.625
201709 23.190 246.819 31.377
201712 35.739 246.524 48.414
201803 35.277 249.554 47.208
201806 30.329 251.989 40.194
201809 42.039 252.439 55.613
201812 38.654 251.233 51.381
201903 31.655 254.202 41.586
201906 28.070 256.143 36.597
201909 27.954 256.759 36.358
201912 22.994 256.974 29.882
202003 22.070 258.115 28.554
202006 32.701 257.797 42.361
202009 32.308 260.280 41.453
202012 31.136 260.474 39.919
202103 32.102 264.877 40.474
202106 37.996 271.696 46.702
202109 34.623 274.310 42.151
202112 32.213 278.802 38.585
202203 32.975 287.504 38.302
202206 31.895 296.311 35.947
202209 34.091 296.808 38.357
202212 19.013 296.797 21.393
202303 34.586 301.836 38.266
202306 28.794 305.109 31.516
202309 19.708 307.789 21.383
202312 34.267 306.746 37.306
202403 31.463 312.332 33.641
202406 26.988 314.175 28.687
202409 32.902 315.301 34.848
202412 53.879 315.605 57.011
202503 47.946 319.799 50.068
202506 46.617 322.561 48.263
202509 44.355 324.800 45.605
202512 47.014 324.054 48.450
202603 41.879 330.213 42.353
202606 41.783 333.952 41.783

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Fermenta Biotech (NSE:FERMENTA) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fermenta Biotech and its competitors.
Is Fermenta Biotech's Cyclically Adjusted Revenue per Share too high?
Fermenta Biotech's current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Fermenta Biotech has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fermenta Biotech's Cyclically Adjusted Revenue per Share compare to ?
Fermenta Biotech's Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fermenta Biotech and its competitors. Fermenta Biotech's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fermenta Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fermenta Biotech (NSE:FERMENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹315.37, compared to a current price of ₹456.10 — trading 44.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Fermenta Biotech's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fermenta Biotech (NSE:FERMENTA), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fermenta Biotech (NSE:FERMENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Fermenta Biotech stock appears to be overvalued. The current stock price of ₹456.10 is trading 44.6% above its estimated GF Value™ of ₹315.37. GuruFocus considers Fermenta Biotech to be Significantly Overvalued.

Key valuation signals for NSE:FERMENTA:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹315.37 vs. price of ₹456.10 (44.6% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the NSE:FERMENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fermenta Biotech Business Description

Comparable Companies
Other Exchanges 506414:India
Address Ghodbunder Road, A -1501, Thane One, DIL Complex, Majiwada, Thane (West), Thane, MH, IND, 400610
Fermenta Biotech Ltd is engaged in the business of manufacturing and marketing chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products and renting and selling properties. It is a manufacturer and supplier of Vitamin D and also supplies Penicillin G Amidase, CAL B Lipase, Polymer Supports, and enzyme technologies. The company operates in two segments namely Property and Bulk Drugs/Chemicals. The majority of the revenue comes from the Bulk Drug/Chemicals segment. Geographically, it caters to both domestic and international markets and generates maximum revenue from the Indian market.
54GF Score

Get the complete analysis for NSE:FERMENTA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹456.10
Price
₹315.37
GF Value